Effect of melatonin versus placebo on clinical outcomes in patients with ischemic stroke

Phase 3

• Conditions: Acute ischemia stoke.; Cerebral ischemia; I67.82

• Registration Number: IRCT20120215009014N378
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

Age:18 to 85 years old
Acute ischemic stroke for the first time
Occurrence of stroke within the past 24 hours
Focal neurological disorder
NIHSS score of at least 4 and at most 27

Exclusion Criteria

Pregnancy or breastfeeding
Acute or chronic intracranial hemorrhage or aneurism
Any type of cognitive or behavioral disorder
Concurrent inflammatory disease
Taking any antioxidant combination in the last month
Sensitivity to melatonin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The severity of neurological function. Timepoint: Before the intervention and on the fifth day and one and three months after the intervention. Method of measurement: Using the National Institutes of Health Stroke (NIHSS) questionnaire and the modified Rankin Scale (mRS) questionnaire.